Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.90 |
| ▸ | FLT1 | P17948 | 16/20 | 0.90 |
| ▸ | FGFR1 | P11362 | 15/20 | 0.90 |
| ▸ | EGFR | P00533 | 13/20 | 0.90 |
| ▸ | FLT4 | P35916 | 12/20 | 0.90 |
| ▸ | AURKA | O14965 | 2/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.72 |
| ▸ | TEK | Q02763 | 2/20 | 0.72 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.72 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1468148 | 0.99 | KDR (0.89) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL7864669 | 0.95 | KDR (1.00) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL1467339 | 0.94 | FLT1 (0.90) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL7867152 | 0.94 | KDR (0.98) | KDRFLT1FGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL1468342 | 0.93 | FLT1 (0.89) | KDRFLT1FGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL7864665 | 0.93 | KDR (1.00) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL1467878 | 0.92 | KDR (1.00) | KDRFLT1FGFR1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL1468298 | 0.91 | KDR (0.98) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL1467348 | 0.89 | FLT1 (1.00) | KDRFLT1FGFR1EGFRFLT4 | |
| SCHEMBL1468087 | 0.88 | FGFR1 (0.98) | KDRFLT1FGFR1EGFRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42353-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2011-05-10 | — | — | US | claimed |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 2011-03-24 | — | — | US | claimed |
| JP-3438818-B2 | — | — | 2003-08-18 | — | — | JP | claimed |
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED | 2002-11-21 | — | — | US | claimed |
| EP-0929530-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2002-11-20 | — | — | EP | claimed |
| US-6414148-B1 | PRODUCE ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT IN WARM-BLOODED ANIMALS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | claimed |
| JP-2001500891-A | — | — | 2001-01-23 | — | — | JP | claimed |
| EP-0929530-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | claimed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | claimed |
| US-RE42353-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2011-05-10 | — | — | US | disclosed |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| US-6897210-B2 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED | 2004-12-02 | — | — | US | disclosed |
| EP-0929530-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2002-11-20 | — | — | EP | disclosed |
| US-6414148-B1 | PRODUCE ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT IN WARM-BLOODED ANIMALS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, FLT1, NR5A1 | KDR 6/4885FLT1 2/4885FGFR1 177/4885 |
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, FLT1, VEGFA | KDR 4/4885FLT1 2/4885FGFR1 195/4885 |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NR5A1, NR5A2, CNKSR1 | KDR 13/4885FLT1 8/4885FGFR1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.